First Patient Dosed in Phase II Study of TLX250-CDx in Triple-Negative Breast Cancer

By
Justin.choi
-
0
9
Telix Pharmaceuticals Limited announced that a first patient has been dosed in a Phase II study of TLX250-CDx in patients with TNBC.
[Telix Pharmaceuticals]

Sorry, but the selected Zotpress account can't be found.

Press Release